Déjà vu? FDA Gives Fast-Track Approval for Questionable $26,500/year Alzheimer’s Drug Similar to Controversial $28,000/year Drug

By B.N. Frank In July 2021, the Food and Drug Administration (FDA) approved a controversial Alzheimer’s drug that Wasn’t necessarily safe or effective Was priced…

Déjà vu? FDA Gives Fast-Track Approval for Questionable $26,500/year Alzheimer’s Drug Similar to Controversial $28,000/year Drug